Special Issue

Development of Therapeutics for the Treatment of Alzheimer's Disease

Message from the Guest Editor

Alzheimer's disease affects 30-35 million people across the globe and is likely to present an increasing demand on medical, social care and economic resources. This disease is not just a function of growing old; there are certain molecular mechanisms/hypotheses that drive the development of pathological damage and cognitive decline. These include tau phosphorylation, neuroinflammation, the role of N-methyl-D-aspartate receptors and several others. This Special Issue focuses on recent research advances around the development of the rapeutics for the treatment of Alzheimer's disease. Original articles related to novel biological approaches in this area or the discovery of small molecule/biologics for this type of dementia are warmly welcomed. Relevant reviews and papers detailing biological pathways will be considered for acceptance. In addition, articles that impinge on pharmacological studies, innovative in vitro/in vivo work, in silico methods and/or chemically driven studies are also invited. Dr. Stephen Wren

Guest Editor

Dr. Stephen P. Wren

Department of Chemical and Pharmaceutical Sciences, Kingston University London, London KT1 2EE, UK

Deadline for manuscript submissions

closed (31 December 2022)



Biology

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.4 Indexed in PubMed



mdpi.com/si/66399

Biology Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 biology@mdpi.com

mdpi.com/journal/ biology





Biology

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.4 Indexed in PubMed





Message from the Editorial Board

A major strength of biological science is the diversity of approaches that biological scientists apply to their research problems. *Biology* reflects this diversity and brings together studies employing the varied experimental and theoretical approaches that are fueling biological discovery. *Biology*, the journal, is a fully peer-reviewed publication with a rapid and economical route to open access publication and is listed on PubMed. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editors-in-Chief

Prof. Dr. Jukka Finne

Research Programme in Molecular and Integrative Biosciences, Faculty of Biological and Environmental Sciences, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland

Prof. Dr. Andrés Moya

Integrative Systems Biology Institute, University of Valencia and CSIC, 46980 Valencia, Spain

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (General Agricultural and Biological Sciences)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

